FDMT 4D Molecular Therapeutics, Inc.
$11.96▲ +8.43%
Healthcare
Other
After hours
$11.96▲ +0.00%
Oct 27, 4:49 PM ET
Volume 1.13M
Avg Volume (10D) 1.02M
Key Metrics & Fundamentals
Market Cap
$660.72M
P/E Ratio
–
Div Yield
0.00%
52W Range
6.96 - 16.93
% vs 50 MA
-14.05%
% vs 200 MA
10.69%
RSI-14
43.8
MACD Histogram
-0.1200
Beta (1Y vs SPY)
1.73
Free Cash Flow
-$70.05M
Gross Rev
$3.78M
Gross Profit
$3.78M
EBITDA
-$74.94M
COGS
–
Operating Exp
$80.81M
Operating Income
-$77.03M
EBIT
-$77.03M
Pretax Income
-$72.94M
Net Income
-$72.94M
EPS (Diluted)
-1.04
Price & Volume History
Loading chart…
Recent News
4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
MarketBeat · Oct 22, 2026 7:02 AM ET
Cystic Fibrosis Market Poised for Growth During the Forecast Period (2026-2036) as CFTR Modulators Transform Treatment Landscape | DelveInsight
PR Newswire · Oct 21, 2026 10:31 AM ET
4DMT Announces New Employment Inducement Grants
GlobeNewswire · Oct 16, 2026 4:05 PM ET
4D Molecular Therapeutics Insider Sold Shares Worth $753,937, According to a Recent SEC Filing
MT Newswires · Oct 7, 2026 5:18 PM ET
4DMT to Host Investor Day on October 21, 2026
GlobeNewswire · Oct 5, 2026 8:00 AM ET
This is the top biotech stock pick from B Riley Securities
Investing.com · Sep 29, 2026 5:24 PM ET
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
Stocktwits · Sep 28, 2026 1:15 PM ET
4D Molecular Therapeutics Begins Phase 3 Trial of 4D-150 in Diabetic Macular Edema
MT Newswires · Sep 28, 2026 9:03 AM ET
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
GlobeNewswire · Sep 28, 2026 8:00 AM ET
4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing
MT Newswires · Sep 16, 2026 5:25 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See FDMT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.